Booming antibodies 2001
MasterControl - Learn How to Avoid Obstacles in Pharma Manufacturing
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

M8 Pharmaceuticals and Gennisium Pharma announce an exclusive License and Distribution Agreement of an orphan hybrid drug

Wednesday, April 29, 2020

The US Pharmaceutical Company m8 Pharmaceuticals and the French Corporation Gennisium Pharma jointly announced that they have entered into an exclusive agreement under which m8 has the exclusive rights to register and commercialize a more suitable formulation of an already existing orphan drug for apnea in Mexico and Brazil, actually the most commonly used medication for treatment and prevention of apnea of prematurity (AOP). Additional pipeline products for the treatment of conditions prevalent in premature newborn patients are also included in this partnership.

Apnea of prematurity (AOP) is a condition in which premature infants, born before 34 weeks of gestational age, stop breathing for 15 to 20 seconds and can be accompanied by hypoxia or bradycardia in serious episodes. The incidence of AOP is inversely correlated with gestational age and birth weight: seven percent of neonates born at 34 to 35 weeks gestation, 15% at 32 to 33 weeks, 54% at 30 to 31 weeks, and nearly all infants born at less than 29 weeks gestation or 1,000 grams exhibit AOP.

According to World Health Organization, an estimated 15 million babies are born too early every year, that is more than 1 in 10 babies. The in-utero development is disrupted for premature newborns, giving birth to infants with immature organs. Most of these immaturities involve some complications which are often interrelated, and this situation impacts the growth, maturation and ultimately healthy development of preterm infants.

Most proposed therapeutic solutions stem from adults treatments and are often not suitable to this vulnerable patient population. Specific treatments and prophylactic therapies for neonates are underdeveloped by the pharmaceutical industry, making important to provide and expand medications that responds to critical health needs of preterm infants.

This agreement is aligned with both companies' strategic imperatives and they shall begin working together with immediate effect to bring these solutions to Latin American patients.

Joel Barlan, m8's CEO, said: "We are delighted to be working with Gennisium Pharma. This new partnership represents a significant addition to our portfolio and within our strategy; in one way, it will allow us to strengthen our Orphan Drug portfolio and further consolidate our presence in Neonatology area, thus bringing benefits to other sectors of the population. By working with Gennisium Pharma we will be able to demonstrate our ability to leverage the knowledge and our unique expertise to establish and make grow leading products. Also, it will help to advance our mission of improve the lives of patients with more access to better treatments, specifically in Brazil, one of the 10 countries with the greatest number of preterm births."

Furthermore, Franck Pigache, Gennisium Pharma's CEO mentioned: "We are very pleased to have signed this licensing agreement with m8, a successful company with several years of experience in registering and marketing medicines on niche and orphan drugs in Brazil and Mexico. We intend to build up a dedicated business for neonatology and prematurity therapeutic area from m8 within these countries. Our first product should be approved by European Health Agency (EMA) by the end of the year in AOP and the current exclusive agreement reflects our willingness to expand our presence outside Europe with key partners."

The partnership represents the opportunity for further collaboration between companies and constitutes a solid pillar for their growth strategy.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEA Catalent - Clinical Supply Solutions Bora Pharmaceuticals - CMDO making success Medical Fair Asia 2022 Medical Manufacturing Asia 2022